已收录 273616 条政策
 政策提纲
  • 暂无提纲
Oral and Non-Oral Combination Therapy for Erectile Dysfunction
[摘要] An estimated 30 million men in the United States suffer from varying degrees of erectile dysfunction. Increasing age and comorbidities are likely to increase the number of men who are initially refractory or become refractory to phosphodiesterase (PDE)-5 inhibitors, the most popular oral therapy. Combination therapy, a concept well proved in other areas of medicine, is therefore of increasing importance. Combination oral and non-oral (intracavernosal injection and intraurethral application) therapies have been shown to salvage monotherapy. The early introduction of combination therapy has been shown to expedite both the return of natural function and PDE-5 inhibitor responsiveness in post-prostatectomy patients with no reports of serious adverse events. Larger controlled studies are needed to corroborate those encouraging findings.
[发布日期]  [发布机构] 
[效力级别]  [学科分类] 基础医学
[关键词] Erectile dysfunction;Intracavernosal injection;Intraurethral application;Phosphodiesterase inhibitors;Alprostadil [时效性] 
   浏览次数:2      统一登录查看全文      激活码登录查看全文